Ursolic acid combined with HDAC2 inhibitor inhibits proliferation of human hepatoma cell line HepG2

Abstract

Abstract: Objective To investigate the effect of ursolic acid (UA) combined with HDAC2 inhibitor (SA) on the growth and proliferation of human hepatocarcinoma cell line HepG2 and its potential mechanism. Methods CCK-8, optical microscopy, cell clone formation and flow cytometry were used to evaluate the inhibitory effects of UA and SA on HepG2 cells after UA and SA monotherapy or combination therapy. Western blot was used to analyze the expression of HDAC2, AC-α-tubulin CDK2, CDK1, Bax, Bcl-2, and cleaved-PARP in the HepG2 cells after the treatment. Results UA had a significant inhibitory effect on the growth of HepG2 with a concentration and time-dependent manner (P＜0.01); UA inhibited HepG2 cell cloning, and the inhibitory effect was more significant when combined with SA (P＜0.01). UA combined with SA blocked HepG2 cell cycle at G₁ phase (P＜0.01); HDAC2 was highly expressed in human hepatoma SMMC-7721, HepG2, and PLC5 cell lines, and UA combined with SA significantly down-regulated HDAC2, Bcl-2, CDK2 and cyclin E1 protein expression, while up-regulated the expression of AC-α-tubulin, Bax and cleaved-PARP. Conclusions The combined application of UA and SA has a synergistic inhibitory effect on the proliferation of HepG2 cells.

Key words: ursolic acid, liver cancer, histone deacetylase 2 (HDAC2), proliferation

CLC Number:

R735.2

TANG Jia-feng, HE Xue-lian, XIA Jing, XIONG Wei, LI Xiao-shan. Ursolic acid combined with HDAC2 inhibitor inhibits proliferation of human hepatoma cell line HepG2[J]. Basic & Clinical Medicine, 2021, 41(8): 1144-1150.

References

[1]Kern MA, Breuhahn K, Schuchmann M, et al. Molecular pathogenesis of hepatocellular carcinoma: new therapeutic approaches and predictive pathology[J]. Pathologe, 2007, 28: 261-268.
[2]Liu AM, Wu QH, Peng DP, et al. A novel strategy for the diagnosis, prognosis, treatment, and chemoresistance of hepatocellular carcinoma: DNA methylation[J]. Med Res Rev, 2020, 40: 1973-2018.
[3]Cabral LKD, Tiribelli C, Sukowati CHC. Sorafenib resistance in hepatocellular carcinoma: the relevance of genetic heterogeneity[J]. Cancers (Basel), 2020,12:1576. doi: 10.3390/cancers12061576.
[4]Zhang C, Jiang WQ, Ding J. New insights on sorafenib resistance in liver cancer with correlation of individualized therapy[J]. Biochim Biophys Acta Rev Cancer, 2020, 1874: 188382. doi: 10.1016/j.bbcan.2020.188382.
[5]Feng XM, Su XL. Anticancer effect of ursolic acid via mitochondria-dependent pathways[J]. Oncol Lett, 2019, 17: 4761-4767.
[6]雷达,李永利,祁军安.熊果酸对HepG2增殖和凋亡的影响及部分机制研究[J].中国现代普通外科进展,2017,20:259-263.
[7]虞燕霞,尚尔宁,陈伯文.熊果酸通过内质网应激通路诱导肝癌SMMC-7721细胞凋亡[J].江苏医药,2016,42:1000-1003.
[8]Ler SY, Leung CW, Khin LW, et al. HDAC1 and HDAC2 independently predict mortality in hepatocellular carcinoma by a competing risk regression model in a Southeast Asian population[J]. Oncol Rep, 2015, 34: 2238-2250.
[9]周力.熊果酸诱导人肝癌细胞株HepG2凋亡的分子机制研究[J].中国现代医学杂志, 2015,25:24-28.
[10]Khan O, La TNB. HDAC inhibitors in cancer biology: emerging mechanisms and clinical applications[J]. Immunol Cell Biol, 2012, 90: 85-94.
[11]Yang C, Choy E, Hornicek FJ, et al. Histone deacetylase inhibitor (HDACI) PCI-24781 potentiates cytotoxic effects of doxorubicin in bone sarcoma cells[J]. Cancer Chemother Pharmacol, 2011, 67: 439-446.
[12]Asghar U, Witkiewicz AK, Turner NC, et al. The history and future of targeting cyclin-dependent kinases in cancer therapy[J]. Nat Rev Drug Discov, 2015, 14: 130-146.

[1]	XIAO Yanhong, JIANG Mingdong, LIN Yeyuan, RAN Can, LIANG Bo. Scutellarin inhibits proliferation and migration of human prostate cancer cell line PC-3 [J]. Basic & Clinical Medicine, 2024, 44(9): 1229-1235.
[2]	YAO Anjun, CHEN Lingzi, JIN Huixian. Docosahexaenoic acid inhibits proliferation of human colon cancer cell line HT-29 [J]. Basic & Clinical Medicine, 2024, 44(8): 1107-1112.
[3]	ZHENG Hong, CHEN Xiaoxia, HAN Lizhou, CHEN Miao, HUANGFU Juan. Decrease of lncRNA-RMRP expression inhibits proliferation and invasion of human lung cancer cell line A549 [J]. Basic & Clinical Medicine, 2024, 44(7): 974-978.
[4]	CAO Qingwen, QI Lin, YU Bo, TIAN Chenchen, YUAN Haining, WANG Yue. Salidroside promotes proliferation and migration of human vascular endothelial cell line EA.hy926 [J]. Basic & Clinical Medicine, 2024, 44(7): 925-930.
[5]	ZHANG Pengju, LI Jie, ZHANG Mengdi, SUN Shaoke, XU Yinzhe. KAT8 promotes the proliferation of colorectal cancer cell lines by enhancing METTL3 expression [J]. Basic & Clinical Medicine, 2024, 44(7): 931-939.
[6]	GAO Yinjie, TONG Anli. Mechanisms of cell death and proliferation of aldosterone-producing adenoma [J]. Basic & Clinical Medicine, 2024, 44(6): 758-762.
[7]	WANG Tingting, XIAO Ning, LIN Dianxin, DONG Haitao. Allicin inhibits the proliferation of oral cancer cells line CAL27 [J]. Basic & Clinical Medicine, 2024, 44(5): 673-676.
[8]	JIA Anna, GUO Jinxin, ZHANG Xuan, ZHAN Shijia, YU Yongbo, GUO Yongli, CHANG Yan. Regulation of TMEFF1 on proliferation of neuroblastoma cell lines [J]. Basic & Clinical Medicine, 2024, 44(5): 637-644.
[9]	LIANG Xiangcun, WEI Xiaoyu, LIANG Jian, WANG Qing, GENG Guang. Anlotinib inhibits proliferation and promotes apoptosis of human non-small cell lung cancer cell lines through miR-16-5p/PD-1 axis [J]. Basic & Clinical Medicine, 2024, 44(4): 503-512.
[10]	LU Kai, LU Jianju, GUO Wenli, HUANG Jianqi, LI Zhihua. lncRNA VIM-AS5 expression and its effect on proliferation and migration of human breast cancer cell lines [J]. Basic & Clinical Medicine, 2024, 44(4): 447-453.
[11]	GUO Hongjiang, XU Yeting, ZHANG Diya, QIU Jiaxing, WANG Yucheng, JU Rui, GUO Lei. Effect of carboxyamidotriazole-orotate on proliferation and fatty acid anabolism of human pancreatic cancer cell lines [J]. Basic & Clinical Medicine, 2024, 44(4): 440-446.
[12]	LI Na, LI Tao, YANG Dongli, YAO Yuan. Honokiol inhibits the proliferation of human adipose-derived mesenchymal stem cells [J]. Basic & Clinical Medicine, 2024, 44(4): 483-488.
[13]	ZHANG Jing, YANG Zigeng, CAI Wenqin, CAO Weiwei, WEI Hongmei, XUE Xixi, WU Bin. Inhibition of prohibitin 2 enhances the sensitivity of non-small cell lung cancer cell line A549 to erlotinib [J]. Basic & Clinical Medicine, 2024, 44(3): 325-332.
[14]	AN Qi, QI Guangzhao, HAN Chao. Aucubin inhibits the proliferation of human hepatocellular carcinoma cells line HepG2 [J]. Basic & Clinical Medicine, 2024, 44(3): 333-338.
[15]	GUO Xin, JI Mengdie, WANG Qi, LI Xueyuan, CHEN Yang. Identification of the effect of cisplatin on the transcriptome of human hepatocellular carcinoma cell lines [J]. Basic & Clinical Medicine, 2024, 44(3): 352-360.